Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2014 | 09-2014 | 06-2014 | 03-2014 | 12-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,284,000 | 1,380,000 | 841,000 | 375,000 | 2,576,000 |
| Depreciation Amortization | 1,548,000 | 1,153,000 | 798,000 | 398,000 | 1,719,000 |
| Accounts receivable | -195,000 | -173,000 | -76,000 | 82,000 | -113,000 |
| Other Working Capital | -490,000 | -376,000 | -217,000 | -8,000 | -1,237,000 |
| Other Operating Activity | 528,000 | 453,000 | -110,000 | -511,000 | 379,000 |
| Operating Cash Flow | $3,675,000 | $2,437,000 | $1,236,000 | $336,000 | $3,324,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | 3,358,000 | N/A | N/A | N/A |
| PPE Investments | -1,077,000 | -790,000 | -513,000 | -255,000 | -1,145,000 |
| Net Acquisitions | -3,312,000 | -2,822,000 | N/A | N/A | -580,000 |
| Purchase Of Investment | -1,507,000 | N/A | 1,119,000 | N/A | -10,064,000 |
| Sale Of Investment | 5,624,000 | N/A | N/A | -367,000 | 7,839,000 |
| Other Investing Activity | 70,000 | 62,000 | 27,000 | 27,000 | 21,000 |
| Investing Cash Flow | $-202,000 | $-192,000 | $633,000 | $-595,000 | $-3,929,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,343,000 | 1,269,000 | 872,000 | 1,213,000 | 2,086,000 |
| Debt Issued | N/A | 0 | N/A | 0 | 9,000 |
| Debt Repayment | -577,000 | 0 | N/A | 0 | -303,000 |
| Common Stock Issued | 429,000 | 290,000 | 226,000 | 170,000 | 395,000 |
| Common Stock Repurchased | -2,195,000 | -2,194,000 | -2,193,000 | -2,192,000 | -1,605,000 |
| Dividend Paid | -1,342,000 | -1,007,000 | -676,000 | -343,000 | -882,000 |
| Other Financing Activity | -400,000 | -400,000 | 0 | 0 | -6,396,000 |
| Financing Cash Flow | $-2,742,000 | $-2,042,000 | $-1,771,000 | $-1,152,000 | $-6,696,000 |
| Exchange Rate Effect | -143,000 | -65,000 | -3,000 | -4,000 | -26,000 |
| Beginning Cash Position | 3,475,000 | 3,475,000 | 3,475,000 | 3,475,000 | 10,802,000 |
| End Cash Position | 4,063,000 | 3,613,000 | 3,570,000 | 2,060,000 | 3,475,000 |
| Net Cash Flow | $588,000 | $138,000 | $95,000 | $-1,415,000 | $-7,327,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,675,000 | 2,437,000 | 1,236,000 | 336,000 | 3,324,000 |
| Capital Expenditure | -1,077,000 | -790,000 | -513,000 | -255,000 | -1,145,000 |
| Free Cash Flow | 2,598,000 | 1,647,000 | 723,000 | 81,000 | 2,179,000 |